Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Acting Cabotegravir/Rilpivirine Reduces Immune-Activation and -Senescence in People With HIV With CMV Co-Infection.

Immunology·2026
Same author

TTV virome marks immune exhaustion, α7nAChR alteration, and mortality in elderly patients with severe COPD.

GeroScience·2026
Same author

Previous COVID-19 Vaccination Modulates Type I Interferon and Natural Killer Cell Responses During SARS-CoV-2 Infection.

Journal of cellular and molecular medicine·2026
Same author

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study.

Pediatric pulmonology·2026
Same author

Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors.

PloS one·2026
Same author

In vitro evaluation of the novel antibiotic zosurabalpin against carbapenem-resistant Acinetobacter baumannii clinical isolates.

Journal of global antimicrobial resistance·2026
Same journal

Corrigendum to "Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination" [International Journal of Antimicrobial Agents, 57 (2021) 106277].

International journal of antimicrobial agents·2026
Same journal

Ecr positively regulates the activity of the PhoQ/PhoP signaling system in Klebsiella pneumoniae.

International journal of antimicrobial agents·2026
Same journal

Contribution of the Arg-33-His Replacement in the Histidine Kinase CpxA to Carbapenem and Cefiderocol Resistance in Serratia marcescens.

International journal of antimicrobial agents·2026
Same journal

Real world evaluation of HIV-1 reservoir and resistance in virologically suppressed people after 52 weeks of treatment with long-acting cabotegravir + rilpivirine.

International journal of antimicrobial agents·2026
Same journal

Molecular and Epidemiological Characteristics of Cefiderocol-Resistant Klebsiella pneumoniae: A Systematic Review and Genomic Analysis.

International journal of antimicrobial agents·2026
Same journal

Timing and regimen of antiretroviral therapy and all-cause mortality in people with HIV: A time-to-event mediation analysis via opportunistic infection.

International journal of antimicrobial agents·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Antiviral therapy: old and current issues.

Guido Antonelli1, Ombretta Turriziani

  • 1Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina 28, 00185 Rome, Italy. guido.antonelli@uniroma1.it

International Journal of Antimicrobial Agents
|June 26, 2012
PubMed
Summary
This summary is machine-generated.

This review discusses emerging challenges in antiviral drug therapy for viral infections like HIV and hepatitis. Addressing these issues is crucial for improving patient management and advancing antiviral treatments.

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: May 21, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • Numerous antiviral medications are approved for treating viral infections such as HIV, HSV, VZV, RSV, CMV, HBV, HCV, and influenza.
  • Significant progress has been made in understanding viral disease natural history and pathogenesis, alongside continuous advancements in antiviral therapies.

Purpose of the Study:

  • To review and discuss previously unknown and unexpected issues arising in antiviral therapy.
  • To highlight the importance of addressing these emerging challenges for enhanced patient management.

Main Methods:

  • Literature review of current antiviral drug approvals and clinical use.
  • Analysis of recent advances in virology and pathogenesis.
  • Identification and discussion of emerging challenges in antiviral research and treatment.

Main Results:

  • Approved antiviral drugs target a range of significant viral infections.
  • Ongoing research continually improves antiviral therapies.
  • New and unforeseen challenges in antiviral treatment are emerging.

Conclusions:

  • Despite advances, antiviral research faces new and unexpected obstacles.
  • Careful consideration of these emerging issues is essential for optimizing patient care.
  • Further research is needed to address these challenges and improve antiviral strategies.